These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31149509)

  • 1. Promising response to axitinib rechallenge for metastatic renal cell carcinoma after progression on prior axitinib: report of two cases.
    Miyake H; Harada KI; Fujisawa M
    Int Cancer Conf J; 2018 Jan; 7(1):30-34. PubMed ID: 31149509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
    Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
    J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
    Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
    Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
    Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
    J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report.
    Murata M; Ikeda Y; Hasegawa G; Nakagawa Y; Nishiyama T
    J Med Case Rep; 2019 Apr; 13(1):98. PubMed ID: 31006385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib Rechallenge Restores the Anticancer Effect after Nivolumab: A Case Report.
    Chang YS; Chang PH; Wang DH; Chen CB; Huang CF
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib rechallenge in metastatic renal cell carcinoma patients.
    Zama IN; Hutson TE; Elson P; Cleary JM; Choueiri TK; Heng DY; Ramaiya N; Michaelson MD; Garcia JA; Knox JJ; Escudier B; Rini BI
    Cancer; 2010 Dec; 116(23):5400-6. PubMed ID: 21105118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.
    Oudard S; Geoffrois L; Guillot A; Chevreau C; Deville JL; Falkowski S; Boyle H; Baciuchka M; Gimel P; Laguerre B; Laramas M; Pfister C; Topart D; Rolland F; Legouffe E; Denechere G; Amela EY; Abadie-Lacourtoisie S; Gross-Goupil M
    Eur J Cancer; 2016 Jul; 62():28-35. PubMed ID: 27192659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
    Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
    BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.
    Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Med Oncol; 2018 Nov; 36(1):6. PubMed ID: 30474747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma.
    Oudard S; Vano Y
    Curr Opin Urol; 2015 Sep; 25(5):402-10. PubMed ID: 26148068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
    Miyake H; Harada KI; Ozono S; Fujisawa M
    Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study.
    Qin S; Bi F; Jin J; Cheng Y; Guo J; Ren X; Huang Y; Tarazi J; Tang J; Chen C; Kim S; Ye D
    Onco Targets Ther; 2015; 8():1363-73. PubMed ID: 26089686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma.
    Kasahara R; Nakaigawa N; Kobayashi K
    Case Rep Oncol Med; 2017; 2017():2648471. PubMed ID: 29085688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study.
    Kadono Y; Konaka H; Izumi K; Anai S; Fujimoto K; Ishibashi K; Kawai N; Kato T; Iba A; Masumori N; Yoshimura K; Mizokami A
    Contemp Clin Trials Commun; 2019 Sep; 15():100403. PubMed ID: 31312749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib in sequential therapy in metastatic renal cell carcinoma.
    Kuchar A; Hryciuk B; Stec R; Mączewski M; Szczylik C
    Contemp Oncol (Pozn); 2016; 20(5):418-420. PubMed ID: 28373826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.